Cancer is a complex disease whereby multiple genetic aberrations, epigenetic modifications, metabolic reprogramming, and the microenvironment contribute to the development of a tumor. In the traditional anticancer drug discovery pipeline, drug candidates are usually screened in vitro using two-dimensional or three-dimensional cell culture. However, these methods fail to accurately mimic the human disease state. This has led to the poor success rate of anticancer drugs in the preclinical stages since many drugs are abandoned due to inefficacy or toxicity when transitioned to whole-organism models. The common fruit fly, Drosophila melanogaster, has emerged as a beneficial system for modeling human cancers. Decades of fundamental research have shown the evolutionary conservation of key genes and signaling pathways between flies and humans. Moreover, Drosophila has a lower genetic redundancy in comparison to mammals. These factors, in addition to the advancement of genetic toolkits for manipulating gene expression, allow for the generation of complex Drosophila genotypes and phenotypes. Numerous studies have successfully created Drosophila models for colorectal, lung, thyroid, and brain cancers. These models were utilized in the high-throughput screening of FDA-approved drugs which led to the identification of several compounds capable of reducing proliferation and rescuing phenotypes. More noteworthy, Drosophila has also unlocked the potential for personalized therapies. Drosophila ‘avatars’ presenting the same mutations as a patient are used to screen multiple therapeutic agents targeting multiple pathways to find the most appropriate combination of drugs. The outcomes of these studies have translated to significant responses in patients with adenoid cystic carcinoma and metastatic colorectal cancers. Despite not being widely utilized, the concept of in vivo screening of drugs in Drosophila is making significant contributions to the current drug discovery pipeline. In this review, we discuss the application of Drosophila as a platform in anticancer drug discovery; with special focus on the cancer models that have been generated, drug libraries that have been screened and the status of personalized therapies. In addition, we elaborate on the biological and technical limitations of this system.
1 February 2020 in Protein Expression and Purification
Hydroxynitrile lyases are used for the synthesis of enantiomerically pure cyanohydrins which are of great importance in the pharmaceutical and fine chemical industries. In this study, the hydroxynitrile lyase activity of 100 plants from 40 families was investigated, first by screening for cyanogenic activity, followed by a hydroxynitrile lyase activity assay. Of the 100 plants, four were found to be cyanogenic and exhibited specific hydroxynitrile lyase activity: Adenia sp. (0.44U/mg), Adenia firingalavensis (2.88U/mg), Adenia fruticosa (1.99U/mg) and, Adenia pechuelii (2.35U/mg), all from the family Passifloraceae. This is the first report of hydroxynitrile lyase activity in these plants
Background: Ezetimibe is used to treat cardiovascular disease as it blocks the sterol transporter Niemann-Pick C1-Like 1 (NPC1CL1) protein. However, recent evidence indicates that Ezetimibe inhibits several cancers indirectly by reducing circulating cholesterol or via specific signalling pathways. Methods and Results: Our in silico studies indicate that Ezetimibe binds to the Tp53 binding domain in Mdm2, forming a more thermodynamically stable complex than nutlin3a. Furthermore, a docking study of the newly developed inhibitors—RG7388 and RG7112—was conducted. This further showed lower binding energies of −6.337 kcal/mol and −6.222 kcal/mol, respectively, when compared to the −7.919 kcal/mol exhibited by Ezetimibe. We show that Ezetimibe inhibits the growth of several cancer cell lines at concentrations that are not toxic to a normal cell line. Conclusions: Thus, Ezetimibe is probably active against cancers that overexpress Mdm2. Moreover, inhibitors of RBBP6 may be combined with Ezetimibe for effective anticancer activity. Due to poor oral bioavailability, Ezetimibe must be administered parenterally for cancer treatment.
Although immune checkpoint inhibitors (ICIs) have shown survival benefits for patients with metastatic cancers, some challenges have been under intense study in recent years. The most critical challenges include the side effects and the emergence of resistance. Potential opportunities exist to develop personalized immune checkpoint inhibitor therapy based on biomarker discovery. Combinational therapy involving immune checkpoint inhibitors and other forms of anticancer therapies has varied success. This chapter reviews drugs currently undergoing Phase III clinical trials and others that are FDA-approved. We take a critical look at the combinational strategies and address the ever-present challenge of resistance. Moreover, we review and evaluate the discovery of biomarkers and assess prospects for personalized immune checkpoint therapy.
This dataset presents the first transcriptome for Phlebodium aureum ‘Mandaianum’, a naturally cyanogenic fern known for producing an (R)-selective hydroxynitrile lyase (HNL) enzyme. Total RNA was extracted from frond tissue and sequenced using the Illumina HiSeq 2500 platform. Following quality control processes, the reads were assembled de novo into 76 562 transcripts. The transcripts had a mean sequence length of 954 bp and an N50 of 1 427 bp. BUSCO analysis showed that 76.5 % of genes were complete, 16.5 % were fragmented, and 7 % were missing. The translated transcriptome was then annotated with COG, GO, EC, KEGG and Pfam using eggNOG Mapper. This resource will support the identification of the HNL gene for heterologous expression, the investigation of genes involved in secondary metabolite biosynthesis, and the exploration of metabolic pathways in ferns. It also serves as a reference for comparative transcriptomics, evolutionary studies, and functional genomics in related plant taxa.